TCM
VRTX icon

Tuttle Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tuttle Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,986
Closed -$540K – 257
2020
Q3 		$540K Buy
1,986
+949
+92% +$262K 0.37% 64
2020
Q2 		$301K Buy
+1,037
New +$281K 0.21% 103
2019
Q2 		– Sell
-2,627
Closed -$483K – 193
2019
Q1 		$483K Buy
+2,627
New +$485K 0.1% 148

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Tuttle Capital Management's VRTX Position: Q4 2020 in Review

Tuttle Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 1,986 shares — an estimated $540K sold.

Tuttle Capital Management first reported a position in VRTX in Q1 2019 and held it in 3 quarters. The position peaked at $540K in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Tuttle Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Tuttle Capital Management sold 1,986 Vertex Pharmaceuticals shares in Q4 2020, an estimated $540K.
  • Tuttle Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Tuttle Capital Management's Vertex Pharmaceuticals position peaked at $540K in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Tuttle Capital Management's 13F filing for Q4 2020, filed 20 Jan 2021.